Ikena Oncology Inc (IKNA)

$1.3

-0.03

(-2.26%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Ikena Oncology Inc

  • Decreasing Revenue

    Revenue is down for the last 6 quarters, 6.40M → 659.0K (in $), with an average decrease of 33.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -12.92M → -19.48M (in $), with an average decrease of 15.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 114.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 325.0%

Performance

  • $1.29
    $1.38
    $1.30
    downward going graph

    0.77%

    Downside

    Day's Volatility :6.52%

    Upside

    5.8%

    downward going graph
  • $1.02
    $7.64
    $1.30
    downward going graph

    21.54%

    Downside

    52 Weeks Volatility :86.65%

    Upside

    82.98%

    downward going graph

Returns

PeriodIkena Oncology IncSector (Health Care)Index (Russel 2000)
3 Months
-7.14%
-0.7%
0.0%
6 Months
-62.75%
9.2%
0.0%
1 Year
-73.74%
3.5%
-1.3%
3 Years
-93.79%
12.3%
-22.1%

Highlights

Market Capitalization
64.2M
Book Value
$3.52
Earnings Per Share (EPS)
-1.63
Wall Street Target Price
8.33
Profit Margin
0.0%
Operating Margin TTM
-3324.43%
Return On Assets TTM
-25.87%
Return On Equity TTM
-43.04%
Revenue TTM
9.2M
Revenue Per Share TTM
0.22
Quarterly Revenue Growth YOY
-87.9%
Gross Profit TTM
-48.7M
EBITDA
-74.4M
Diluted Eps TTM
-1.63
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.55
EPS Estimate Next Year
-1.34
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Ikena Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 540.77%

Current $1.30
Target $8.33

Company Financials

FY19Y/Y Change
Revenue
13.8M
-
Net Income
-16.8M
-
Net Profit Margin
-122.28%
-
FY20Y/Y Change
Revenue
9.2M
↓ 33.15%
Net Income
-44.3M
↑ 163.16%
Net Profit Margin
-481.36%
↓ 359.08%
FY21Y/Y Change
Revenue
31.0M
↑ 237.01%
Net Income
-34.1M
↓ 22.91%
Net Profit Margin
-110.1%
↑ 371.26%
FY22Y/Y Change
Revenue
15.6M
↓ 49.59%
Net Income
-66.6M
↑ 95.3%
Net Profit Margin
-426.6%
↓ 316.5%
FY23Y/Y Change
Revenue
9.2M
↓ 41.35%
Net Income
-68.2M
↑ 2.31%
Net Profit Margin
-744.17%
↓ 317.57%
Q3 FY22Q/Q Change
Revenue
6.4M
↑ 1575.92%
Net Income
-16.8M
↓ 16.13%
Net Profit Margin
-262.42%
↑ 4981.3%
Q4 FY22Q/Q Change
Revenue
5.5M
↓ 14.87%
Net Income
-13.1M
↓ 22.14%
Net Profit Margin
-240.0%
↑ 22.42%
Q1 FY23Q/Q Change
Revenue
5.3M
↓ 2.51%
Net Income
-12.9M
↓ 1.2%
Net Profit Margin
-243.23%
↓ 3.23%
Q2 FY23Q/Q Change
Revenue
2.0M
↓ 62.28%
Net Income
-17.1M
↑ 32.44%
Net Profit Margin
-854.04%
↓ 610.81%
Q3 FY23Q/Q Change
Revenue
1.2M
↓ 40.87%
Net Income
-17.3M
↑ 1.33%
Net Profit Margin
-1.5K%
↓ 609.5%
Q4 FY23Q/Q Change
Revenue
659.0K
↓ 44.39%
Net Income
-19.5M
↑ 12.37%
Net Profit Margin
-3.0K%
↓ 1493.82%
FY19Y/Y Change
Total Assets
86.0M
-
Total Liabilities
147.4M
-
FY20Y/Y Change
Total Assets
168.4M
↑ 95.88%
Total Liabilities
269.5M
↑ 82.76%
FY21Y/Y Change
Total Assets
247.9M
↑ 47.19%
Total Liabilities
40.0M
↓ 85.15%
FY22Y/Y Change
Total Assets
172.3M
↓ 30.51%
Total Liabilities
25.3M
↓ 36.78%
FY23Y/Y Change
Total Assets
192.1M
↑ 11.51%
Total Liabilities
22.3M
↓ 11.68%
Q3 FY22Q/Q Change
Total Assets
190.5M
↓ 9.81%
Total Liabilities
31.7M
↓ 13.95%
Q4 FY22Q/Q Change
Total Assets
172.3M
↓ 9.56%
Total Liabilities
25.3M
↓ 20.17%
Q1 FY23Q/Q Change
Total Assets
152.4M
↓ 11.53%
Total Liabilities
17.4M
↓ 31.28%
Q2 FY23Q/Q Change
Total Assets
171.8M
↑ 12.71%
Total Liabilities
15.1M
↓ 13.32%
Q3 FY23Q/Q Change
Total Assets
215.3M
↑ 25.37%
Total Liabilities
60.0M
↑ 298.24%
Q4 FY23Q/Q Change
Total Assets
192.1M
↓ 10.79%
Total Liabilities
22.3M
↓ 62.77%
FY18Y/Y Change
Operating Cash Flow
-11.6M
-
Investing Cash Flow
11.0M
-
Financing Cash Flow
16.3M
-
FY19Y/Y Change
Operating Cash Flow
47.9M
↓ 512.88%
Investing Cash Flow
-316.0K
↓ 102.88%
Financing Cash Flow
16.3M
↑ 0.0%
FY20Y/Y Change
Operating Cash Flow
-37.8M
↓ 178.92%
Investing Cash Flow
2.9M
↓ 1024.68%
Financing Cash Flow
116.2M
↑ 612.09%
FY21Y/Y Change
Operating Cash Flow
-60.3M
↑ 59.29%
Investing Cash Flow
-1.8M
↓ 160.23%
Financing Cash Flow
131.7M
↑ 13.39%
FY22Y/Y Change
Operating Cash Flow
-74.1M
↑ 23.0%
Investing Cash Flow
-99.3M
↑ 5541.14%
Financing Cash Flow
1.1M
↓ 99.17%
Q3 FY22Q/Q Change
Operating Cash Flow
-17.2M
↓ 11.47%
Investing Cash Flow
35.8M
↑ 74.67%
Financing Cash Flow
24.0K
↓ 95.83%
Q4 FY22Q/Q Change
Operating Cash Flow
-17.7M
↑ 2.53%
Investing Cash Flow
10.5M
↓ 70.66%
Financing Cash Flow
1000.0
↓ 95.83%
Q1 FY23Q/Q Change
Operating Cash Flow
-19.8M
↑ 12.06%
Investing Cash Flow
-10.8M
↓ 202.92%
Financing Cash Flow
37.0M
↑ 3700100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.1M
↓ 8.29%
Investing Cash Flow
22.7M
↓ 309.88%
Financing Cash Flow
37.0M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Ikena Oncology Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ikena Oncology Inc
Ikena Oncology Inc
-9.72%
-62.75%
-73.74%
-93.79%
-95.94%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ikena Oncology Inc
Ikena Oncology Inc
5.29
NA
NA
-1.55
-0.43
-0.26
NA
3.52
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ikena Oncology Inc
Ikena Oncology Inc
Buy
$64.2M
-95.94%
5.29
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • FMR Inc

    8.67%
  • Orbimed Advisors, LLC

    7.33%
  • Bvf Inc

    6.57%
  • Omega Fund Management LLC

    4.66%
  • CHI Advisors LLC

    4.52%
  • Blue Owl Capital Holdings LP

    4.05%

Company Information

ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi

Organization
Ikena Oncology Inc
Employees
43
CEO
Dr. Mark Manfredi Ph.D.
Industry
Services

FAQs